loperamide has been researched along with Breast Neoplasms in 6 studies
Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.
loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Supportive treatment with loperamide is associated with constipation." | 9.69 | Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B). ( Doi, M; Iwasa, T; Masuda, H; Matsumoto, K; Miyoshi, Y; Niikura, N; Sagara, Y; Sakai, H; Shimomura, A; Takahashi, M; Takano, T; Tanabe, Y; Tokunaga, S; Tsurutani, J; Yoshimura, K, 2023) |
| " Primary endpoints included: incidence of investigator assessed severe (≥ Grade 3), prolonged (> 7 days) Grade 2 diarrhea, treatment discontinuation, dose modifications, and loperamide utilization during the first 3 cycles of treatment." | 9.51 | An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer. ( Boyle, F; Chapman, SC; Chen, Y; Ezquerra, MB; Gable, JC; Gainford, MC; Goksu, SS; Hossain, AM; Lim, E; Loi, S; Okera, M; Price, GL; van Hal, G, 2022) |
| " Supportive treatment with loperamide is associated with constipation." | 5.69 | Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B). ( Doi, M; Iwasa, T; Masuda, H; Matsumoto, K; Miyoshi, Y; Niikura, N; Sagara, Y; Sakai, H; Shimomura, A; Takahashi, M; Takano, T; Tanabe, Y; Tokunaga, S; Tsurutani, J; Yoshimura, K, 2023) |
| " Primary endpoints included: incidence of investigator assessed severe (≥ Grade 3), prolonged (> 7 days) Grade 2 diarrhea, treatment discontinuation, dose modifications, and loperamide utilization during the first 3 cycles of treatment." | 5.51 | An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer. ( Boyle, F; Chapman, SC; Chen, Y; Ezquerra, MB; Gable, JC; Gainford, MC; Goksu, SS; Hossain, AM; Lim, E; Loi, S; Okera, M; Price, GL; van Hal, G, 2022) |
| "Loperamide is an FDA-approved antidiarrhea drug which acts on the μ-opioid receptors in the mesenteric plexus of large intestine and exhibits limited side effects." | 5.38 | Loperamide, an FDA-approved antidiarrhea drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin-induced cytotoxicity. ( Gu, X; Sha, W; Shan, L; Sridhar, R; Sukumar, S; Zhou, Y, 2012) |
| " All strategies reduced grade ≥3 diarrhea with the lowest incidence in DE1 (DE1 13%; colestipol + loperamide [CL] 21%, DE2 27%; budesonide + loperamide [BL] 28%; loperamide [L] 31%; colestipol + loperamide as needed [CL-PRN] 33%)." | 4.31 | Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. ( Barcenas, CH; Bose, R; Brufsky, A; Chan, A; Cheong, KA; Chien, AJ; DiPrimeo, D; Egle, D; Foruzan, N; García-Sáenz, JA; Hurvitz, SA; Marx, G; McCulloch, L; Pistilli, B; Rugo, HS; Ruiz-Borrego, M; Schnappauf, B; Semsek, D; Singer, CF; Thirlwell, M; Trudeau, M; Wassermann, J, 2023) |
| " Treatment with 100 microM buprenorphine, a representative analgesic, induced cell death of human carcinomas, such as A549 (squamous epithelial cell of lung cancer), MCF-7 (breast cancer) and N417 (small cell of lung cancer), but not in KATO III (gastric cancer) cells as evaluated by alamar blue assay." | 3.70 | Opioid analgesic-induced apoptosis and caspase-independent cell death in human lung carcinoma A549 cells. ( Iwamura, T; Tokuyama, S; Ueda, H; Yoshida, A, 2000) |
| "Loperamide is an FDA-approved antidiarrhea drug which acts on the μ-opioid receptors in the mesenteric plexus of large intestine and exhibits limited side effects." | 1.38 | Loperamide, an FDA-approved antidiarrhea drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin-induced cytotoxicity. ( Gu, X; Sha, W; Shan, L; Sridhar, R; Sukumar, S; Zhou, Y, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lim, E | 1 |
| Boyle, F | 1 |
| Okera, M | 1 |
| Loi, S | 1 |
| Goksu, SS | 1 |
| van Hal, G | 1 |
| Chapman, SC | 1 |
| Gable, JC | 1 |
| Chen, Y | 1 |
| Price, GL | 1 |
| Hossain, AM | 1 |
| Gainford, MC | 1 |
| Ezquerra, MB | 1 |
| Chan, A | 1 |
| Ruiz-Borrego, M | 1 |
| Marx, G | 1 |
| Chien, AJ | 2 |
| Rugo, HS | 2 |
| Brufsky, A | 1 |
| Thirlwell, M | 1 |
| Trudeau, M | 1 |
| Bose, R | 1 |
| García-Sáenz, JA | 1 |
| Egle, D | 1 |
| Pistilli, B | 1 |
| Wassermann, J | 1 |
| Cheong, KA | 1 |
| Schnappauf, B | 1 |
| Semsek, D | 1 |
| Singer, CF | 1 |
| Foruzan, N | 1 |
| DiPrimeo, D | 1 |
| McCulloch, L | 1 |
| Hurvitz, SA | 1 |
| Barcenas, CH | 1 |
| Masuda, H | 1 |
| Tanabe, Y | 1 |
| Sakai, H | 1 |
| Matsumoto, K | 1 |
| Shimomura, A | 1 |
| Doi, M | 1 |
| Miyoshi, Y | 1 |
| Takahashi, M | 1 |
| Sagara, Y | 1 |
| Tokunaga, S | 1 |
| Iwasa, T | 1 |
| Niikura, N | 1 |
| Yoshimura, K | 1 |
| Takano, T | 1 |
| Tsurutani, J | 1 |
| Jacob, S | 1 |
| Johnson, M | 1 |
| Roque, B | 1 |
| Quintal, L | 1 |
| Melisko, M | 1 |
| Zhou, Y | 1 |
| Sridhar, R | 1 |
| Shan, L | 1 |
| Sha, W | 1 |
| Gu, X | 1 |
| Sukumar, S | 1 |
| Yoshida, A | 1 |
| Tokuyama, S | 1 |
| Iwamura, T | 1 |
| Ueda, H | 1 |
3 trials available for loperamide and Breast Neoplasms
| Article | Year |
|---|---|
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Di | 2022 |
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Di | 2022 |
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Di | 2022 |
Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B).
Topics: Breast Neoplasms; Constipation; Diarrhea; Female; Humans; Loperamide; Probiotics; Quality of Life; T | 2023 |
Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B).
Topics: Breast Neoplasms; Constipation; Diarrhea; Female; Humans; Loperamide; Probiotics; Quality of Life; T | 2023 |
Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B).
Topics: Breast Neoplasms; Constipation; Diarrhea; Female; Humans; Loperamide; Probiotics; Quality of Life; T | 2023 |
Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Female; Humans; Loperami | 2023 |
Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Female; Humans; Loperami | 2023 |
Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Female; Humans; Loperami | 2023 |
3 other studies available for loperamide and Breast Neoplasms
| Article | Year |
|---|---|
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Budesonide; Colestipol; Diarrhea; | 2023 |
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Budesonide; Colestipol; Diarrhea; | 2023 |
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Budesonide; Colestipol; Diarrhea; | 2023 |
Loperamide, an FDA-approved antidiarrhea drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin-induced cytotoxicity.
Topics: Antibiotics, Antineoplastic; Antidiarrheals; ATP Binding Cassette Transporter, Subfamily B; ATP Bind | 2012 |
Loperamide, an FDA-approved antidiarrhea drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin-induced cytotoxicity.
Topics: Antibiotics, Antineoplastic; Antidiarrheals; ATP Binding Cassette Transporter, Subfamily B; ATP Bind | 2012 |
Loperamide, an FDA-approved antidiarrhea drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin-induced cytotoxicity.
Topics: Antibiotics, Antineoplastic; Antidiarrheals; ATP Binding Cassette Transporter, Subfamily B; ATP Bind | 2012 |
Opioid analgesic-induced apoptosis and caspase-independent cell death in human lung carcinoma A549 cells.
Topics: Analgesics, Opioid; Apoptosis; Breast Neoplasms; Buprenorphine; Carcinoma, Small Cell; Carcinoma, Sq | 2000 |
Opioid analgesic-induced apoptosis and caspase-independent cell death in human lung carcinoma A549 cells.
Topics: Analgesics, Opioid; Apoptosis; Breast Neoplasms; Buprenorphine; Carcinoma, Small Cell; Carcinoma, Sq | 2000 |
Opioid analgesic-induced apoptosis and caspase-independent cell death in human lung carcinoma A549 cells.
Topics: Analgesics, Opioid; Apoptosis; Breast Neoplasms; Buprenorphine; Carcinoma, Small Cell; Carcinoma, Sq | 2000 |